Table of Contents

1 Report Overview

• 1.1 Research Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Recombinant Protein Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Recombinant DNA
  • 1.3.3 Recombinant RNA
• 1.4 Market Segment by Application
  • 1.4.1 Global Recombinant Protein Drugs Market Share by Application (2019-2025)
  • 1.4.2 Pharmaceutical Industry
  • 1.4.3 Other
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Production and Capacity Analysis
  • 2.1.1 Global Recombinant Protein Drugs Production Value 2014-2025
  • 2.1.2 Global Recombinant Protein Drugs Production 2014-2025
  • 2.1.3 Global Recombinant Protein Drugs Capacity 2014-2025
  • 2.1.4 Global Recombinant Protein Drugs Marketing Pricing and Trends
• 2.2 Key Producers Growth Rate (CAGR) 2019-2025
  • 2.2.1 Global Recombinant Protein Drugs Market Size CAGR of Key Regions
  • 2.2.2 Global Recombinant Protein Drugs Market Share of Key Regions
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Capacity and Production by Manufacturers
  • 3.1.1 Global Recombinant Protein Drugs Capacity by Manufacturers
  • 3.1.2 Global Recombinant Protein Drugs Production by Manufacturers
• 3.2 Revenue by Manufacturers
  • 3.2.1 Recombinant Protein Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Recombinant Protein Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Recombinant Protein Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Recombinant Protein Drugs Price by Manufacturers
• 3.4 Key Manufacturers Recombinant Protein Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Recombinant Protein Drugs Market
• 3.6 Key Manufacturers Recombinant Protein Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Production and Production Value for Each Type
  • 4.1.1 Recombinant DNA Production and Production Value (2014-2019)
  • 4.1.2 Recombinant RNA Production and Production Value (2014-2019)
• 4.2 Global Recombinant Protein Drugs Production Market Share by Type
• 4.3 Global Recombinant Protein Drugs Production Value Market Share by Type
• 4.4 Recombinant Protein Drugs Ex-factory Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Recombinant Protein Drugs Consumption by Application

6 Production by Regions

• 6.1 Global Recombinant Protein Drugs Production (History Data) by Regions 2014-2019
• 6.2 Global Recombinant Protein Drugs Production Value (History Data) by Regions
• 6.3 United States
  • 6.3.1 United States Recombinant Protein Drugs Production Growth Rate 2014-2019
  • 6.3.2 United States Recombinant Protein Drugs Production Value Growth Rate 2014-2019
  • 6.3.3 Key Players in United States
  • 6.3.4 United States Recombinant Protein Drugs Import & Export
• 6.4 European Union
  • 6.4.1 European Union Recombinant Protein Drugs Production Growth Rate 2014-2019
  • 6.4.2 European Union Recombinant Protein Drugs Production Value Growth Rate 2014-2019
  • 6.4.3 Key Players in European Union
  • 6.4.4 European Union Recombinant Protein Drugs Import & Export
• 6.5 China
  • 6.5.1 China Recombinant Protein Drugs Production Growth Rate 2014-2019
  • 6.5.2 China Recombinant Protein Drugs Production Value Growth Rate 2014-2019
  • 6.5.3 Key Players in China
  • 6.5.4 China Recombinant Protein Drugs Import & Export
• 6.6 Rest of World
  • 6.6.1 Japan
  • 6.6.2 Korea
  • 6.6.3 India
  • 6.6.4 Southeast Asia

7 Recombinant Protein Drugs Consumption by Regions

• 7.1 Global Recombinant Protein Drugs Consumption (History Data) by Regions
• 7.2 United States
  • 7.2.1 United States Recombinant Protein Drugs Consumption by Type
  • 7.2.2 United States Recombinant Protein Drugs Consumption by Application
• 7.3 European Union
  • 7.3.1 European Union Recombinant Protein Drugs Consumption by Type
  • 7.3.2 European Union Recombinant Protein Drugs Consumption by Application
• 7.4 China
  • 7.4.1 China Recombinant Protein Drugs Consumption by Type
  • 7.4.2 China Recombinant Protein Drugs Consumption by Application
• 7.5 Rest of World
  • 7.5.1 Rest of World Recombinant Protein Drugs Consumption by Type
  • 7.5.2 Rest of World Recombinant Protein Drugs Consumption by Application
  • 7.5.1 Japan
  • 7.5.2 Korea
  • 7.5.3 India
  • 7.5.4 Southeast Asia

8 Company Profiles

• 8.1 Novo Nordisk
  • 8.1.1 Novo Nordisk Company Details
  • 8.1.2 Company Description and Business Overview
  • 8.1.3 Production and Revenue of Recombinant Protein Drugs
  • 8.1.4 Recombinant Protein Drugs Product Introduction
  • 8.1.5 Novo Nordisk Recent Development
• 8.2 Amgen
  • 8.2.1 Amgen Company Details
  • 8.2.2 Company Description and Business Overview
  • 8.2.3 Production and Revenue of Recombinant Protein Drugs
  • 8.2.4 Recombinant Protein Drugs Product Introduction
  • 8.2.5 Amgen Recent Development
• 8.3 Sanofi
  • 8.3.1 Sanofi Company Details
  • 8.3.2 Company Description and Business Overview
  • 8.3.3 Production and Revenue of Recombinant Protein Drugs
  • 8.3.4 Recombinant Protein Drugs Product Introduction
  • 8.3.5 Sanofi Recent Development
• 8.4 Eli Lilly
  • 8.4.1 Eli Lilly Company Details
  • 8.4.2 Company Description and Business Overview
  • 8.4.3 Production and Revenue of Recombinant Protein Drugs
  • 8.4.4 Recombinant Protein Drugs Product Introduction
  • 8.4.5 Eli Lilly Recent Development
• 8.5 Merck Serono
  • 8.5.1 Merck Serono Company Details
  • 8.5.2 Company Description and Business Overview
  • 8.5.3 Production and Revenue of Recombinant Protein Drugs
  • 8.5.4 Recombinant Protein Drugs Product Introduction
  • 8.5.5 Merck Serono Recent Development
• 8.6 Ortho Biotech
  • 8.6.1 Ortho Biotech Company Details
  • 8.6.2 Company Description and Business Overview
  • 8.6.3 Production and Revenue of Recombinant Protein Drugs
  • 8.6.4 Recombinant Protein Drugs Product Introduction
  • 8.6.5 Ortho Biotech Recent Development
• 8.7 Roche
  • 8.7.1 Roche Company Details
  • 8.7.2 Company Description and Business Overview
  • 8.7.3 Production and Revenue of Recombinant Protein Drugs
  • 8.7.4 Recombinant Protein Drugs Product Introduction
  • 8.7.5 Roche Recent Development
• 8.8 Kyowa Hakko Kirin
  • 8.8.1 Kyowa Hakko Kirin Company Details
  • 8.8.2 Company Description and Business Overview
  • 8.8.3 Production and Revenue of Recombinant Protein Drugs
  • 8.8.4 Recombinant Protein Drugs Product Introduction
  • 8.8.5 Kyowa Hakko Kirin Recent Development
• 8.9 Pharmingen
  • 8.9.1 Pharmingen Company Details
  • 8.9.2 Company Description and Business Overview
  • 8.9.3 Production and Revenue of Recombinant Protein Drugs
  • 8.9.4 Recombinant Protein Drugs Product Introduction
  • 8.9.5 Pharmingen Recent Development
• 8.10 Abcam
  • 8.10.1 Abcam Company Details
  • 8.10.2 Company Description and Business Overview
  • 8.10.3 Production and Revenue of Recombinant Protein Drugs
  • 8.10.4 Recombinant Protein Drugs Product Introduction
  • 8.10.5 Abcam Recent Development
• 8.11 GenSci
• 8.12 SL PHARM
• 8.13 Dongbao Pharm
• 8.14 Ankebio
• 8.15 NCPC
• 8.16 Heng Rui

9 Market Forecast

• 9.1 Global Market Size Forecast
  • 9.1.1 Global Recombinant Protein Drugs Capacity, Production Forecast 2019-2025
  • 9.1.2 Global Recombinant Protein Drugs Production Value Forecast 2019-2025
• 9.2 Market Forecast by Regions
  • 9.2.1 Global Recombinant Protein Drugs Production and Value Forecast by Regions 2019-2025
  • 9.2.2 Global Recombinant Protein Drugs Consumption Forecast by Regions 2019-2025
• 9.3 United States
  • 9.3.1 Production and Value Forecast in United States
  • 9.3.2 Consumption Forecast in United States
• 9.4 European Union
  • 9.4.1 Production and Value Forecast in European Union
  • 9.4.2 Consumption Forecast in European Union
• 9.5 China
  • 9.5.1 Production and Value Forecast in China
  • 9.5.2 Consumption Forecast in China
• 9.6 Rest of World
  • 9.6.1 Japan
  • 9.6.2 Korea
  • 9.6.3 India
  • 9.6.4 Southeast Asia
• 9.7 Forecast by Type
  • 9.7.1 Global Recombinant Protein Drugs Production Forecast by Type
  • 9.7.2 Global Recombinant Protein Drugs Production Value Forecast by Type
• 9.8 Consumption Forecast by Application

10 Value Chain and Sales Channels Analysis

• 10.1 Value Chain Analysis
• 10.2 Sales Channels Analysis
  • 10.2.1 Recombinant Protein Drugs Sales Channels
  • 10.2.2 Recombinant Protein Drugs Distributors
• 10.3 Recombinant Protein Drugs Customers

11 Opportunities & Challenges, Threat and Affecting Factors

• 11.1 Market Opportunities
• 11.2 Market Challenges
• 11.3 Porter's Five Forces Analysis

12 Key Findings

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
    • 13.1.1.1 Research Programs/Design
    • 13.1.1.2 Market Size Estimation
    • 13.1.1.3 Market Breakdown and Data Triangulation
  • 13.1.2 Data Source
    • 13.1.2.1 Secondary Sources
    • 13.1.2.2 Primary Sources
• 13.2 Author Details

In 2019, the market size of Recombinant Protein Drugs is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Recombinant Protein Drugs.

This report studies the global market size of Recombinant Protein Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Recombinant Protein Drugs production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Novo Nordisk
Amgen
Sanofi
Eli Lilly
Merck Serono
Ortho Biotech
Roche
Kyowa Hakko Kirin
Pharmingen
Abcam
GenSci
SL PHARM
Dongbao Pharm
Ankebio
NCPC
Heng Rui

Market Segment by Product Type
Recombinant DNA
Recombinant RNA

Market Segment by Application
Pharmaceutical Industry
Other

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Recombinant Protein Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Recombinant Protein Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Recombinant Protein Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025